Compass Therapeutics Reports 2024 Financial Results and Provides Corporate Update
Compass Therapeutics, Inc. (CMPX)
Company Research
Source: GlobeNewswire
Top-line Phase 2/3 data readout for COMPANION-002, evaluating tovecimig (CTX-009 - a DLL4 x VEGF-A bispecific antibody) in patients with biliary tract cancer (BTC), is on track for the end of the first quarter 2025.Supported initiation of an Investigator Sponsored Study (IST) evaluating tovecimig in patients with BTC in the first-line setting, with patient dosing expected in the first quarter 2025.Continued to advance CTX-10726 (PD-1 x VEGF-A bispecific antibody) towards expected year-end 2025 IND filing, with clinical data expected in 2026.Planning to initiate two Phase 2 clinical trials in mid-2025 using novel biomarkers: tovecimig [in DLL4-positive colorectal cancer (CRC) in combination with chemotherapy] and CTX-471 (in NCAM/CD56 express
Read more
Impact Snapshot
Event Time:
CMPX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CMPX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CMPX alerts
High impacting Compass Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CMPX
News
- Why Compass Therapeutics, Inc. (CMPX) is Skyrocketing So Far in 2025 [Yahoo! Finance]Yahoo! Finance
- Compass Therapeutics, Inc. (NASDAQ: CMPX) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $32.00 price target on the stock.MarketBeat
- Ottimo Pharma Strengthens Leadership Team with Senior Appointments [Yahoo! Finance]Yahoo! Finance
- Compass Therapeutics, Inc. (NASDAQ: CMPX) is now covered by analysts at Guggenheim. They set a "buy" rating and a $12.00 price target on the stock.MarketBeat
- Massachusetts-Based Biotech Soars On Analyst Coverage And Bullish Price Targer [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
CMPX
Earnings
- 11/12/24 - Beat
CMPX
Sec Filings
- 2/27/25 - Form 10-K
- 2/27/25 - Form 8-K
- 2/14/25 - Form SCHEDULE
- CMPX's page on the SEC website